Someday, cicadas and dragonflies might save your sight. The key to this power lies in their wings, which are coated with a forest of tiny pointed pillars that impale and kill bacterial cells unlucky enough to land on them. Now, scientists report they have replicated these antibacterial nanopillars on synthetic polymers that are being developed to restore vision.
American Chemical Society
The researchers present their work today at the 251st National Meeting & Exposition of the American Chemical Society (ACS). ACS, the world's largest scientific society, is holding the meeting here through Thursday. It features more than 12,500 presentations on a wide range of science topics.
"Other research groups have also created antibacterial nanopillar surfaces, but none of their approaches can be used on ordinary polymer surfaces or be scaled up easily," according to Albert F. Yee, Ph.D., who leads a team working on the topic. By contrast, the production method his group is adapting overcomes these hurdles.
"Our method is based on one developed in the early 2000s for the semiconductor industry," says Mary Nora Dickson, a graduate student in Yee's lab. "It is robust, inexpensive and can be used in industrial production. So it can now be applied to medical devices that could improve people's quality of life."
One such application is an artificial cornea that Yee's group aims to construct from poly(methyl methacrylate) (PMMA), familiar to many by trade names such as Plexiglas® and Lucite®. The material is already commonly used in medical devices including implantable intraocular lenses and traditional hard contact lenses. By building nanopillars into the surfaces of these types of devices, the researchers hope to make them bactericidal without the need for a separate biocidal coating or antibiotic drugs.
In earlier work, Yee, Dickson, Elena Liang, and colleagues at the University of California, Irvine, showed that their nanopillars, like those on cicada wings, can kill bacteria referred to as "gram-negative." This group of microorganisms includes E. coli. But cicada nanopillars are unable to kill another type of bacteria known as "gram-positive" because these microbes have thicker cell walls. Wiping out these bacteria, which include MRSA (methicillin-resistant Staphylococcus aureus) and Streptococcus (known as "strep"), is important because they cause infections on medical devices and in hospitals.
Compared to cicada nanopillars, the ones on dragonfly wings are taller and skinnier, and they can kill gram-positive bacteria. Now Dickson is trying to form these types of nanopillars on PMMA. However, she is finding that these structures are harder to replicate than the cicadas' stubby pillars. She is currently modifying the production process in several different ways to overcome these challenges.
For example, one version of the process uses commercial molds that contain billions of tiny pits in an area that covers just a few square inches. Pressing the mold onto a heated polymer film reshapes the film, leaving it decorated with nanopillars once the mold is removed. That method works just fine for the stubbier cicada-like pillars, but the finer dragonfly-like pillars tend to break apart when the mold is removed, much like over-cooked cupcakes sticking to the inside of an ungreased muffin tin.
So Dickson is experimenting with fluorinated silane coatings for the mold; these coatings could help free the pillars when it's time to remove the polymer film. She's also testing different chemical compositions for the mold itself.
Yee, Liang and Dickson are now applying their technique to curved surfaces such as an artificial cornea. For this application, Dickson created a flexible mold for the cicada-like pillars. She recently showed that the nanopillared PMMA surface produced with this curved mold retains the ability to kill bacteria without harming other kinds of cells in the eye. The team is currently developing a mold for the taller, dragonfly-type pillars.
The group has filed for patents on the bactericidal surface and artificial cornea application and hopes to begin animal trials this year.